Loading stock data…
Galectin Therapeutics Inc (GALT)
$4.97-0.02 (-0.40%)
Market ClosedLast close Jun 29
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Galectin Therapeutics Inc. in the Healthcare sector is trading at $4.97 with a market capitalization of $169M. Wall Street consensus targets $11.00 (1 analysts), implying a +121.3% move over the next 12 months. The stock is currently 30% below its 52-week high of $7.13, remaining 33.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +121.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.08M↓ | -$3.37M↑ | -$4.20M↑ | -$4.63M↑ | -$7.90M |
| Net Income | -$5.05M↑ | -$5.50M↑ | -$8.18M↓ | -$7.52M↑ | -$9.63M |
Peer Comparison
JNJUNHPFE
Fundamentals
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$169.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.16%
Volume
Today's trading volume
1.85M
Recent News
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosis program, clarifying a potential path toward full approval.
GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial
Galectin plans to submit the final trial protocol to the FDA in the third quarter of 2026.
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?
Galectin Therapeutics (GALT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps
Galectin Therapeutics (NASDAQ:GALT) hosted a virtual key opinion leader (KOL) event to discuss belapectin as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, a population the speakers described as having substantial un
Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insiders
Key Insights Galectin Therapeutics' significant retail investors ownership suggests that the key decisions are...